Oligonucleotide delivery: a patent review (2010 – 2013)

Bibliography

• Kole R, Krainer AR, Altman S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov 2012;11:125-40
   PubMed Web of Science ®Google Scholar
• Wilson C, Keefe AD. Building oligonucleotide therapeutics using non-natural chemistries. Curr Opin Chem Biol 2006;10:607-14
   PubMed Web of Science ®Google Scholar
• Joergensen M, Agerholm-Larsen B, Nielsen PE, et al. Efficiency of cellular delivery of antisense peptide nucleic acid by electroporation depends on charge and electroporation geometry. Oligonucleotides 2011;21:29-37
   PubMedGoogle Scholar
• Zhou J, Shum K-T, Burnett JC, et al. Nanoparticle-based delivery of RNAi therapeutics: progress and challenges. Pharmaceuticals 2013;6:85-107
   Google Scholar
• Moshfeghi AA, Puliafito CA. Pegaptanib sodium for the treatment of neovascular age-related macular degeneration. Expert Opin Investig Drugs 2005;14:671-82
   PubMed Web of Science ®Google Scholar
• Dixon DL, Sisson EM, Butler M, et al. Lomitapide and mipomersen: novel lipid-lowering agents for the management of familial hypercholesterolemia. J Cardiovasc Nurs 2013. [Epub ahead of print]
   Google Scholar
• de Smet MD, Meenken CJ, van den Horn GJ, et al. Formivirsen – a phosphorothioate oligonucleotide for the treatment of CMV retinitis. Ocul Immunol Inflamm 1999;7:189-98
   PubMed Web of Science ®Google Scholar
• Couto LB, High KA. Viral vector-mediated RNA interference. Curr Opin Pharmacol 2010;5:534-42
   Google Scholar
• Jafari M, Soltani M, Naahidi S, et al. Nonviral approach for targeted nucleic acid delivery. Curr Med Chem 2012;19:197-208
   PubMed Web of Science ®Google Scholar
• Zhi D, Zhang S, Cui S, et al. The headgroup evolution of cationic lipids for gene delivery. Bioconjug Chem 2013;24:487-519
   PubMedGoogle Scholar
• Buyens K, De Smedt SC, Braeckmans K, et al. Liposome based systems for systemic siRNA delivery: stability in blood sets the requirements for optimal carrier design. J Control Release 2012;158:362-70
   PubMed Web of Science ®Google Scholar
• Montana G, Bondi ML, Carrotta R, et al. Employment of cationic solid-lipid nanoparticles as RNA carriers. Bioconjug Chem 2007;18:302-8
   PubMed Web of Science ®Google Scholar
• Yousefi A, Storm G, Schiffelers R, et al. Trends in polymeric delivery of nucleic acids to tumors. J Control Release 2013;170:209-18
   PubMedGoogle Scholar
• Trabulo S, Cardoso AL, Cardoso AM, et al. Cell-penetrating peptides as nucleic acid delivery systems: from biophysics to biological applications. Curr Pharm Des 2013;19:2895-923
   PubMedGoogle Scholar
• Grijalvo S, OCampo SM, Perales JC, et al. Synthesis of oligonucleotides carrying aminolipid groups at the 3’-end for RNA interference studies. J Org Chem 2010;75:6806-13
   PubMedGoogle Scholar
• Troiber C, Wagner E. Nucleic acid carriers based on precise polymer conjugates. Bioconjug Chem 2011;22:1737-52
   PubMedGoogle Scholar
• Liu H, Torring T, Dong M, et al. DNA-templeted covalent coupling of G4 PAMAM dendrimers. J Am Chem Soc 2010;132:18054-6
   PubMedGoogle Scholar
• Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004;432:173-8
   PubMed Web of Science ®Google Scholar
• Jackson AL, Linsley PS. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov 2010;9:57-67
   PubMed Web of Science ®Google Scholar
• Famulok M. Exploring chemical space with aptamers. J Med Chem 2009;52:6951-7
   PubMedGoogle Scholar
• Ruckman JM, Green LS, Beeson J, et al. 2’-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). J Biol Chem 1998;273:20556-67
   PubMed Web of Science ®Google Scholar
• Semple SC, Akinc A, Chen J, et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 2010;28:172-6
   PubMed Web of Science ®Google Scholar
• Müller RH, Shegokar R, Keck CM. 20 years of lipid nanoparticles (SLN and NLC): present state of development and industrial applications. Curr Drug Discov Technol 2011;8:207-27
   PubMedGoogle Scholar
• Templeton N. Cationic liposomes as in vivo delivery vehicles. Biosci Rep 2002;22:283-95
   PubMed Web of Science ®Google Scholar
• Zimmermann TS, Lee AC, Akinc A, et al. RNAi-mediated gene silencing in non-human primates. Nature 2006;441:111-14
   PubMed Web of Science ®Google Scholar
• Gomes da Silva L, Fonseca NA, Moura V, et al. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges. Acc Chem Res 2012;45:1163-71
   PubMedGoogle Scholar
• de Fougerolles A, Vornlocher H-P, Maraganore J, et al. Interference with disease: a progress report on siRNA-based therapeutics. Nature Rev. Drug Discov 2007;6:443-53
   Google Scholar
• Alnylam Pharmaceuticals. Di-aliphatic substituted pegylated lipids. WO2013049328 A1; 2013
   Google Scholar
• Alnylam Pharmaceuticals. Pegylated lipids and their use for drug delivery. WO2012099755 A1; 2012
   Google Scholar
• Abbott Laboratories. Cationic lipids and uses thereof. US20100055168 A1; US20100055169 A1; 2010
   Google Scholar
• Akinc A, Zumbuehl A, Goldberg M, et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 2008;26:561-9
   PubMed Web of Science ®Google Scholar
• Zhang J, Fan H, Levorse DA, et al. Ionization behavior of amino lipids for siRNA delivery: determination of ionization constants, SAR and the impact of lipid pKa on cationic lipid-biomembrane interactions. Langmuir 2011;27:1907-14
   PubMed Web of Science ®Google Scholar
• Jayaraman M, Ansell SM, Mui BL, et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew Chem Int Ed 2012;51:8529-33
   PubMed Web of Science ®Google Scholar
• Alnylam Pharmaceuticals. Biodegradable lipids for the delivery of active agents. WO2013086354 A1; WO201153493 A1; 2011
   Google Scholar
• Alnylam Pharmaceuticals. Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of nucleic acids. WO2013086322 A1; 2013
   Google Scholar
• Merck Sharp & Dohme Corporation. Novel low molecular weight cationic lipids for oligonucleotide delivery. WO2012054365 A2; 2012, WO2011153120 A1; 2011
   Google Scholar
• Merck Sharp & Dohme Corporation. Novel low molecular weight, biodegradable cationic lipids for oligonucleotide delivery. WO2013116126 A1; 2013
   Google Scholar
• Merck Sharp & Dohme Corporation. Novel diester and triester based low molecular weight, biodegradable cationic lipids for oligonucleotide delivery. WO2013158579 A1; 2013
   Google Scholar
• Merck Sharp & Dohme Corporation. Low molecular weight cationic lipids for oligonucleotide delivery. WO2012044638 A1; 2012
   Google Scholar
• Merck Sharp & Dohme Corporation. Diether based biodegradable cationic lipids for siRNA delivery. WO2013148541 A1; 2013
   Google Scholar
• Merck Sharp & Dohme Corporation. Novel cationic lipids with various head groups for oligonucleotide delivery. WO2011022460 A1; 2011
   Google Scholar
• Merck Sharp & Dohme Corporation. Ring constrained cationic lipids for oligonucleotide delivery. WO2012162210 A1; 2012
   Google Scholar
• Merck Sharp & Dohme Corporation. Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery. WO2012061259 A1; 2012
   Google Scholar
• Alnylam Pharmaceuticals. Branched cationic lipids for nucleic acids delivery system. WO2010056403 A1; 2010
   Google Scholar
• Agave Pharma, Inc. Compositions comprising cationic amphiphiles and colipids for delivering therapeutic molecules. WO2010135207 A1; 2010
   Google Scholar
• Dicerna Pharmaceuticals. Lipids capable of conformational change and their use in formulations to deliver therapeutic agents to cells. WO2013032643 A2; 2013
   Google Scholar
• Wolfrum C, Shi S, Jayaprakash KN, et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol 2007;25:11149-57
   Google Scholar
• Miragen Therapeutics. Lipophilic polynucleotide conjugates. WO2010129672 A1; 2010
   Google Scholar
• Sylentis SAU. Sphingosine-bound siRNA. US2012142765 A1; 2012
   Google Scholar
• Consejo Superior de Investigaciones Científicas. Lipophilic derivatives of nucleic acids. WO2011135138 A1; 2011
   Google Scholar
• F. Hoffmann-LaRoche AG. Small molecule conjugates for intracellular delivery of nucleic acids. WO2012089352 A1; 2012
   Google Scholar
• Isis Innovation. Conjugates for delivery of biologically active compounds. WO2011064552 A1; 2011
   Google Scholar
• Cedars Sinai Medical Center. Targeted delivery system. WO2010085665 A2; 2010
   Google Scholar
• Mayo Foundation for medical education and research. Peptide-mediated delivery of active agents across the blood-brain barrier. WO2013082286 A1; 2013
   Google Scholar
• Coda therapeutics, Inc. Compositions and treatments based on cadherin modulation. WO2013148736 A1; 2013
   Google Scholar
• Beth Israel Deaconess Medical Center, Inc. Chimeric RNA oligonucleotides and uses thereof. WO2012142480 A1; 2012
   Google Scholar
• Yale university. Antimicrobial compositions and methods of use thereof. WO2013044116 A1; 2013
   Google Scholar
• Replicor, Inc. Oligonucleotide chelate complex-polypeptide compositions and methods. WO2013170386 A1; 2013
   Google Scholar
• Cepep AB III, Uelo L, Piret A, et al. A system for cargo delivery into the cells. WO2012113846 A1; 2012
   Google Scholar
• Lundberg P, El-Andaloussi S, Sutlu T, et al. Delivery of short interfering RNA using endosomolytic cell-penetrating peptides. FASEB J 2007;21:2664-71
   PubMed Web of Science ®Google Scholar
• Sloan-Kettering institute for cancer research. Peptide-conjugated oligonucleotide therapeutic and method of making and using same. US2011003754 A1; 2011
   Google Scholar
• AVI Biopharma, Inc. Peptide-oligonucleotide conjugate. WO2012150960 A1; 2012
   Google Scholar
• Gait MJ, Arzumanov AA, Saleh AF, et al. Peptides. WO2013030569 A2; 2013
   Google Scholar
• Ahmed K, El Andaloussi S, Guterstam P, et al. Chemically modified cell-penetrating peptides for improved delivery of gene modulating compounds. WO2010039088 A1; 2010
   Google Scholar
• Commissariat a l’energie atomique et aux energies alternatives, INSERM, Universite Joseph Fourier. Small efficient cell penetrating peptides derived from the scoerpion toxin Maurocalcine. WO2012176138 A2; 2012
   Google Scholar
• Dicerna Pharmaceuticals, Inc. Phase changing formulations of nucleic acids payloads. WO2012173994 A2; 2012
   Google Scholar
• Cenix Bioscience GmbH. Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes. WO2012101235 A1; 2012
   Google Scholar
• National University Corp. Tokyo Medical and Dental University. System for delivering nucleic acids for suppressing target gene expression by utilizing endogenous chylomicron. US2010234282 A1; 2010
   Google Scholar
• Access Pharmaceuticals, Inc. Multivitamin targeting of RNAi therapeutics. WO2012030745 A1; 2012
   Google Scholar
• Endocyte, Inc., and Perdue Research Foundation. Folate targeting of nucleotides. WO2010045584 A1; 2010
   Google Scholar
• Consejo Superior de Investigaciones Cientificas. Modified oligonucleotides as regulators of gene expression. WO2011135141 A1; 2011
   Google Scholar
• Goorve Biopharma Corp. Enhanced biodistribution of oligomers. WO2012119051 A2; 2012
   Google Scholar
• The University of North Caroline at Chapell Hill. Targeted intracellular delivery of oligonucleotides via conjugation with small molecule ligands. WO2011126937 A1; 2011
   Google Scholar
• Arrowhead Madison, Inc. Peptide-based in vivo siRNA delivery system. US2013281658 A1; 2013
   Google Scholar
• Alnylam Pharmaceuticals. RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases. WO2013075035 A1; 2013
   Google Scholar
• Merck, Sharp & Dohme Corp. Novel tetragalnac containing conjugates and methods for delivery of oligonucleotides. WO2013166121 A1; 2013
   Google Scholar
• Arrowhead Res Corp. Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA. KR20137015388 20111215; 2013
   Google Scholar
• Burghes A. Non-ionic, low osmolar contrast agents for delivery of antisense oligonucleotides and treatment of disease. WO2013086207 A1; 2013
   Google Scholar
• Hoffmann La Roche AG. Integrin antagonist conjugates for targeted delivery to cells expressing alpha-V-beta-3. WO2013110679 A1; 2013
   Google Scholar
• Hoffmann La Roche AG. Integrin antagonist conjugates for targeted delivery to cells expressing LFA-1. WO2013110679 A1; 2013
   Google Scholar
• Hoffmann La Roche AG. Integrin antagonist conjugates for targeted delivery to cells expressing VLA-4. WO2013110680 A1; 2013
   Google Scholar
• The University of North Caroline at Chapell Hill and Commissariat a l’energie atomique et aux energies alternatives. Small molecules that enhance the activity of oligonucleotides. WO2013123217 A1; 2013
   Google Scholar
• GE Healthcare Biosciences AB. System for improved delivery of gene modulating compounds. WO2011115555 A1; 2011
   Google Scholar
• Merck, Sharp & Dohme Corp. Novel single chemical entities and methods for delivery of oligonucleotides. WO2011126974 A1; 2011
   Google Scholar
• University of Miami. Aptamer-targeted siRNA to inhibit non sense mediated decay. WO2011005566 A2; 2011
   Google Scholar
• Smith C. Compositions comprising nucleic acid aptamers. US20100254901 A1; 2010
   Google Scholar
• University of Columbia. Aptamer mediated drug release. WO2010111466 A1; 2010
   Google Scholar
• Krishnendu R, Bilal G, Sudhir K. Modified polysaccharide-based delivery of nucleic acids. US2010311654 A1; 2010
   Google Scholar
• Synedgen, Inc. Nucleic acid delivery using modified chitosans. WO2010088565 A1; 2010
   Google Scholar
• RXI pharmaceuticals Corp. Formulations and methods for targeted delivery to phagocyte cells. WO2011109698 A1; 2011
   Google Scholar
• Chong Kun Dang Pharmaceuticals, Inc. Novel composition for gene delivery. WO2013070010 A1; 2013
   Google Scholar
• University of South Florida. Divalent-metal coated nanoparticles for delivery of compositions into the central nervous system by nasal insufflation. WO2013040295 A2; 2013
   Google Scholar
• RGO Biosciences LLC. Cyclodextrin conjugates. WO2010017328 A2; 2010
   Google Scholar
• Duncan R, Vicent MJ. Polymer therapeutics-prospects for 21st century: the end of the beginning. Adv Drug Deliv Rev 2013;65:60-70
   PubMed Web of Science ®Google Scholar
• University of Strasbourg & CNRS. Polymers for delivering molecules of interest. WO2011120953 A1; 2011
   Google Scholar
• University of Rutgers. Compositions and methods for delivering nucleic acids molecules and treating cancer. WO2012024396 A2; US20110281787 A1; 2012.2011
   Google Scholar
• Cerulean Pharma, Inc. Conjugates, particles, compositions, and related methods. WO2013126564 A1; 2013
   Google Scholar
• Charlotte Mecklenburg Hospital. Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same. WO2011143008 A1; 2011
   Google Scholar
• University of Yale. Polymeric materials loaded with mutagenic and recombinagenic nucleic acids. WO2011053989 A2; 2011
   Google Scholar
• Nanogen Pharmaceuticals. Polymeric nanoparticles and a process of preparation thereof. WO2013160773 A2; 2013
   Google Scholar
• Merck, Sharp & Dohme. Membrane lytic poly(amido-amine) polymers for the delivery of oligonucleotides. WO2012082574 A1; 2012
   Google Scholar
• Merck, Sharp & Dohme. Polyamide polymers for the delivery of oligonucleotides. WO2012068187 A1, WO2011115862 A1; 2012.2011
   Google Scholar
• Merck, Sharp & Dohme. Poly(ornithine) homopolymers for the delivery of oligonucleotides. WO2013016157 A1; 2013
   Google Scholar
• Rozema DB, Wakefield DH. Polyconjugates for in vivo delivery of polynucleotides. US2012230938 A1; 2012
   Google Scholar
• Mersana therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof. WO2011120053 A1; 2011
   Google Scholar
• University of Ferrara. Nanoparticle of the core-shell type suitable for delivering therapeutic oligonucleotides to target tissues and the use thereof for the preparation of a medicament for treating Duchenne muscular dystrophy. WO2011045747 A1; 2011
   Google Scholar
• Rutgers, The State University of New Jersey. Graft copolymer polyelectrolyte complexes for drug delivery. US20130183379 A1; 2013
   Google Scholar
• Alnylam Pharmaceuticals, Inc. Multifunctional copolymers for nucleic acid delivery. WO2011163121 A1; 2011
   Google Scholar
• Yale University. Methods of treating inflammatory and autoimmune diseases and disorders. WO2013155493 A1; 2013
   Google Scholar
• Northwestern University. Delivery of therapeutic agents using oligonucleotide-modified nanoparticles as carriers. WO2011028850 A1; 2011
   Google Scholar
• University of Siracuse. Synthesis and method for delivery of DNA-binding chemotherapy drugs using nanoparticles. WO2012061402 A2; 2012
   Google Scholar
• Dar-Bin S, Chen-Sheng Y, Dong-Huang C, et al. Nano-carrier, complex of anticancer drug and nano-carrier, pharmaceutical composition thereof, method for manufacturing the complex and method for treating cancer by using the pharmaceutical composition. US2012027861 A1; 2012
   Google Scholar
• Northwestern University. Localized delivery of nanoparticles for therapeutic and diagnostic applications. WO2011017456 A2; 2011
   Google Scholar
• University of Chung. Nanoparticle-based gene delivery systems. WO2011055888 A1; 2011
   Google Scholar
• University of California. Cationic polymer-coated mesoporous silica nanoparticles and uses thereof. US20122007795 A1, WO2012009448 A2; 2012
   Google Scholar
• Sloan-Kettering Institute for Cancer Research. Targeted self-assembly of functionalized carbon nanotubes on tumors. WO2013101983 A2; 2013
   Google Scholar
• Sanford Burnham Medical Research institute. Delivery of agents using interfering nanoparticles. WO2011116152 A2; 2011
   Google Scholar